Literature DB >> 23910616

The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review.

Chayawee Muangchant1, Janet E Pope.   

Abstract

OBJECTIVES: Interleukin-6 (IL-6) may play a role in the pathogenesis of SSc. C-reactive protein (CRP), an acute phase reactant induced by IL-6, may be a prognostic marker in SSc. The goal of this systematic review was to address the significance and clinical application of IL-6 and CRP in systemic sclerosis (SSc).
METHODS: A literature search was conducted to identify English-language original articles within PubMed, Scopus, and Medline database from inception to May 30, 2013 using keywords 'systemic sclerosis or scleroderma and C-reactive protein or interleukin-6'.
RESULTS: The search resulted in 156 relevant articles. Some single nucleotide polymorphisms and gene-gene interactions affect SSc predisposition, manifestation and expression of IL-6. Studies in animal models show IL-6 and IL-6 trans-signalling are involved in SSc disease development. Derangements of T and B cells function regulate IL-6 in SSc pathogenesis. Fibroblasts, T/B cells, monocytes, macrophages, dendritic cells and endothelial cells participate in IL-6 expression and interact with each other resulting in tissue sclerosis. Up-regulation of serum IL-6 and CRP levels are evident in SSc patients and associated with disease activity, severity, disability, worse outcome and reduced survival. Targeted IL-6 therapy in SSc has occurred in small cases series and within a multi-site trial that is under way.
CONCLUSIONS: Studies show IL-6 and CRP are important in SSc both in pathogenesis and clinical manifestations and may be useful indicators of disease activity, severity, and poor prognosis. IL-6 could be a relevant treatment target in SSc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23910616

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  16 in total

Review 1.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

2.  Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?

Authors:  Mutlu Hizal; Cosimo Bruni; Eloisa Romano; Celestina Mazzotta; Serena Guiducci; Silvia Bellando Randone; Jelena Blagojevic; Gemma Lepri; Abdurrahman Tufan; Marco Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2015-01-20       Impact factor: 2.980

3.  High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.

Authors:  Thapat Wannarong; Chayawee Muangchan
Journal:  Rheumatol Int       Date:  2018-09-11       Impact factor: 2.631

Review 4.  Targeting interleukin-6 for noninfectious uveitis.

Authors:  Phoebe Lin
Journal:  Clin Ophthalmol       Date:  2015-09-11

5.  MiR-152 may silence translation of CaMK II and induce spontaneous immune tolerance in mouse liver transplantation.

Authors:  Yan Wang; Yang Tian; Yuan Ding; Jingcheng Wang; Sheng Yan; Lin Zhou; Haiyang Xie; Hui Chen; Hui Li; Jinhua Zhang; Jiacong Zhao; Shusen Zheng
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

6.  Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells.

Authors:  Maria L Valle; Janine Dworshak; Ashok Sharma; Ahmed S Ibrahim; Mohamed Al-Shabrawey; Shruti Sharma
Journal:  Exp Eye Res       Date:  2018-09-18       Impact factor: 3.467

7.  Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures.

Authors:  Jaclyn N Taroni; Viktor Martyanov; Chiang-Ching Huang; J Matthew Mahoney; Ikuo Hirano; Brandon Shetuni; Guang-Yu Yang; Darren Brenner; Barbara Jung; Tammara A Wood; Swati Bhattacharyya; Orit Almagor; Jungwha Lee; Arlene Sirajuddin; John Varga; Rowland W Chang; Michael L Whitfield; Monique Hinchcliff
Journal:  Arthritis Res Ther       Date:  2015-07-29       Impact factor: 5.156

8.  The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders.

Authors:  Barna Vasarhelyi; Gergely Toldi; Attila Balog
Journal:  EJIFCC       Date:  2016-04-20

9.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Authors:  Dinesh Khanna; Christopher P Denton; Celia J F Lin; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Helen Spotswood; Laura Burke; Jeffrey Siegel; Angelika Jahreis; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2017-10-24       Impact factor: 19.103

10.  Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis.

Authors:  Debomita Chakraborty; Barbora Šumová; Tatjana Mallano; Chih-Wei Chen; Alfiya Distler; Christina Bergmann; Ingo Ludolph; Raymund E Horch; Kolja Gelse; Andreas Ramming; Oliver Distler; Georg Schett; Ladislav Šenolt; Jörg H W Distler
Journal:  Nat Commun       Date:  2017-10-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.